Metastatic

Type: Keyphrase
Name: Metastatic
First reported 11 hours ago - Updated 59 mins ago - 5 reports

Exelixis slashes workforce by 70 percent after late-stage failure of cabozantinib in prostate cancer

Exelixis announced that it will cut up to 70 percent of its staff, or approximately 160 employees, after the failure of a Phase III trial of cabozantinib in men with metastatic castration-resistant prostate cancer. The company said top-line results from ... [Published FirstWord Pharma - 59 mins ago]
First reported 2 hours ago - Updated 2 hours ago - 1 reports

CTCs and Survival in Breast Cancer Patients

Braun S, Vogl FD, Naume B, et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med . 2005;353(8):793–802.Janni W, Vogl FD, Wiedswang G, et al. Persistence of disseminated tumor cells in the bone marrow of breast cancer patients ... [Published General Medicine eJournal - 2 hours ago]
First reported 3 hours ago - Updated 3 hours ago - 1 reports

FDA Approves Bevacizumab for Aggressive and Late-Stage Cervical Cancer

By The ASCO PostSeptember 1, 2014, Volume 5, Issue 14Figures:The U.S. Food and Drug Administration (FDA) has approved the antiangiogenic agent bevacizumab (Avastin) for the treatment of persistent, recurrent, or metastatic cervical cancer. The new indication ... [Published The ASCO Post - 3 hours ago]
First reported 6 hours ago - Updated 6 hours ago - 1 reports

Ongoing Clinical Trials Actively Recruiting Patients With Kidney Cancer

The information in this Clinical Trials Resource Guide includes actively recruiting clinical studies for patients with kidney cancer. The list includes a pilot study and observational, randomized, and nonrandomized phase II and phase III studies evaluating ... [Published The ASCO Post - 6 hours ago]
First reported 8 hours ago - Updated 8 hours ago - 1 reports

Understanding the Impact of Results From CALGB/ SWOG 80405 and Other New Data in Colorectal Cancer

Figures:Alok A. Khorana, MDThree Takeaways in Colorectal Cancer From ASCO 2014For now, you can use either cetuximab or bevacizumab in first-line treatment of KRAS wild-type metastatic colorectal cancer. Toxicities appear to be similar, median survival ... [Published The ASCO Post - 8 hours ago]
First reported 9 hours ago - Updated 9 hours ago - 1 reports

[News] Sunitinib still first-line therapy for metastatic renal cancer

Everolimus (an mTOR inhibitor) does not yield better results compared with sunitinib (a VEGFR tyrosine kinase inhibitor) as first-line therapy in patients with metastatic renal-cell carcinoma, new research suggests. Cross-study comparisons suggests that ... [Published Lancet Oncology - 9 hours ago]
First reported 9 hours ago - Updated 9 hours ago - 1 reports

[News] NICE guidance on enzalutamide for metastatic hormone-relapsed prostate cancer

, the National Institute for Health and Care Excellence (NICE) recommended enzalutamide, within its marketing authorisation, for the treatment of metastatic hormone-relapsed prostate cancer that has progressed during or after docetaxel-containing chemotherapy, ... [Published Lancet Oncology - 9 hours ago]
First reported 9 hours ago - Updated 9 hours ago - 1 reports

[News] NICE guidance on ipilimumab for treating previously untreated advanced (unresectable or metastatic) melanoma

, the National Institute of Health and Care Excellence (NICE) published guidance recommending ipilimumab as an option for treating adults with previously untreated advanced (unresectable or metastatic) melanoma, as long as the manufacturer provides ipilimumab ... [Published Lancet Oncology - 9 hours ago]
First reported 9 hours ago - Updated 9 hours ago - 1 reports

[Comment] New prostate cancer drugs: extending and improving life

With the advent of new, life-prolonging therapies in advanced prostate cancer, the effects of therapy on the disease's most common complications—skeletal-related events and bone pain—and their effect in turn on health-related quality of life should be ... [Published Lancet Oncology - 9 hours ago]
First reported 9 hours ago - Updated 9 hours ago - 1 reports

[Review] Combination of stereotactic ablative body radiation with targeted therapies

Recent advances allow safe and effective delivery of ablative doses of radiation with stereotactic precision to tumours, resulting in very high levels of tumour control. Parallel advances in the understanding of tumour biology enable delivery of systemic ... [Published Lancet Oncology - 9 hours ago]
First reported Sep 01 2014 - Updated Sep 01 2014 - 1 reports

Proton pump inhibitors (PPIs) impact on tumour cell survival, metastatic potential and chemotherapy ...

Neoadjuvant treatment plays a crucial role in the therapy of advanced esophageal cancer. However, response to radiochemotherapy varies widely.Proton pump inhibitors (PPIs) have been demonstrated to impact on chemotherapy in a variety of other cancers. ... [Published 7thSpace - Sep 01 2014]
First reported Aug 31 2014 - Updated Aug 31 2014 - 2 reports

Was the death of Robin Williams preventable?

In his piece on Robin Williams, Andrew Solomon of the New Yorker states that every 40 seconds, someone commits suicide. Actually, it’s every second of every day, as people choose the action, or inaction, that will end their lives sooner. When the patient ... [Published BioPortfolio - Aug 31 2014]

Quotes

..."We are very disappointed," commented CEO Michael M Morrissey, adding that "the workforce reduction...is necessary to significantly reduce our corporate operating expenses."
...its primary endpoint of extending overall survival in men with mCRPC," said Morrissey, Ph D , president and chief executive officer of Exelixis. "We are grateful to the patients, physicians, nurses, caregivers, and other study team members who participated in the trial. We remain focused on the development program for cabozantinib beyond mCRPC, including the ongoing METEOR and CELESTIAL Phase III pivotal trials, from which we expect top-line data in 2015 and 2017, respectively."
Talking about Biocon's drive against cancer Mr. Shukrit Chimote, Vice President and Head-Branded Formulations, India, said: "As India's leading Oncology Company, Biocon has been making a significant impact in the area of cancer care through its affordable, life-saving therapies. Through this initiative we hope to educate a large number of Indians on the risk factors associated with this killer disease and encourage them to get regular oral screening by qualified doctors, as a means of early cancer detection, that can lead to better treatment outcomes."
"By all accounts, this is truly a breakthrough," Flaherty said. "There's a sense of general enthusiasm that we think is warranted."

More Content

All (1866) | News (1428) | Reports (0) | Blogs (394) | Audio/Video (1) | Fact Sheets (2) | Press Releases (23)
sort by: Date | Relevance
Optimizing Treatment for Bone Metastases in Pat... [Published MyNewsDesk - 24 mins ago]
US Market Changes in the Treatment of Advanced ... [Published MyNewsDesk - 24 mins ago]
US Market Changes in the Treatment of Advanced ... [Published MyNewsDesk - 24 mins ago]
Exelixis slashes workforce by 70 percent after ... [Published FirstWord Pharma - 59 mins ago]
Exelixis prostate cancer drug cabozantinib fail... [Published Pharma Times - 1 hour ago]
CTCs and Survival in Breast Cancer Patients [Published General Medicine eJournal - 2 hours ago]
FDA Approves Bevacizumab for Aggressive and Lat... [Published The ASCO Post - 3 hours ago]
Single-Fraction Radiotherapy for Palliation of ... [Published MedImaging.net - 4 hours ago]
Failure of IGF-1R Inhibitor Figitumumab in Adva... [Published The ASCO Post - 6 hours ago]
Ongoing Clinical Trials Actively Recruiting Pat... [Published The ASCO Post - 6 hours ago]
National Ovarian Cancer Awareness Month on Canc... [Published CancerConnect.com - 7 hours ago]
Phase III Trial of Figitumumab Plus Chemotherap... [Published The ASCO Post - 8 hours ago]
Loss of LKB1 disrupts breast epithelial cell po... [Published 7thSpace - 8 hours ago]
Understanding the Impact of Results From CALGB/... [Published The ASCO Post - 8 hours ago]
Quest for Targeted Therapeutic ‘Cocktails’ Hits... [Published The ASCO Post - 8 hours ago]
[News] NICE guidance on ipilimumab for treating... [Published Lancet Oncology - 9 hours ago]
[Comment] New prostate cancer drugs: extending ... [Published Lancet Oncology - 9 hours ago]
[Comment] Dual targeting of HER2 with lapatinib... [Published Lancet Oncology - 9 hours ago]
[News] NICE guidance on enzalutamide for metast... [Published Lancet Oncology - 9 hours ago]
[Comment] The ProtecT trial: what can we expect? [Published Lancet Oncology - 9 hours ago]
[Review] Combination of stereotactic ablative b... [Published Lancet Oncology - 9 hours ago]
[News] Sunitinib still first-line therapy for m... [Published Lancet Oncology - 9 hours ago]
Exelixis Inc announces results from COMET-1 Pha... [Published Reuters - 9 hours ago]
Cabozantinib flops against prostate cancer, for... [Published FierceBiotech - 10 hours ago]
When will they find a cancer cure, doc? [Published Guardian.co.uk - 10 hours ago]
Exelixis Announces Results from the COMET-1 Pha... [Published Digital Journal - 11 hours ago]
Exelixis Announces Results from the COMET-1 Pha... [Published Town Hall - 11 hours ago]
Exelixis Announces Results from the COMET-1 Pha... [Published Business Wire Health News - 11 hours ago]
NICE holds back on wider use of innovative pros... [Published Trends In Urology & Men's health - 18 hours ago]
Risk of common skin cancer increased by as much... [Published Ecancer Medicalscience - 18 hours ago]
1 2 3 4 5 6 7 8 9 10 ...
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Exelixis Announces Results from the COMET-1 Pha... [Published Business Wire Health News - 11 hours ago]
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ:EXEL) today announced top-line results from the final analysis of COMET-1, the phase 3 pivotal trial of cabozantinib in men with metastatic castration-resistant prostate cancer (mCRPC) ...
Was the death of Robin Williams preventable? [Published KevinMD.com - Aug 31 2014]
In his piece on Robin Williams, Andrew Solomon of the New Yorker states that every 40 seconds, someone commits suicide. Actually, it’s every second of every day, as people choose the action, or inaction, that will end their lives sooner. When the patient ...
Need Help Understanding My Cervical MRI Results! [Published HealthBoards - Aug 31 2014]
I have been having headaches and neck pain for. Few months now so the surgeon who performed my most recent lumbar fusion ordered an MRI to see what was going on. I received a copy of my MRI today and hope somebody can tell me what it all means. When he ...
Doc ordered flexible sigmoidoscopy for constipa... [Published HealthBoards - Aug 30 2014]
I've had 2 strange incidents of constipation, both with blood and one with excruciating pain.After the first incident my primary care doc did a test for hemmoroids and found nothing.He sent me for labs and Pevlic CT.Labs came back clean, but pelvic CT ...
Photos from Panama prison show alleged Quebec f... [Published National Post - Top Stories - Aug 29 2014]
Warning: Graphic Images More than a year after being jailed in La Joya — Panama’s most notorious prison — alleged hospital fraudster Arthur Porter is now sharing with the public the squalid and violent details of his life in Cellblock 6. Those ...
1 2 3 4 5 6 7 8 9 10 ...

Audio/Video

sort by: Date | Relevance
The Fault In Our Stars [Published Slate Magazine - Jun 07 2014]
1

Press Releases

sort by: Date | Relevance
Seragon Pharmaceuticals Inc. Announces Closing ... [Published GlobeNewswire: Acquisitions News - Aug 27 2014]
Merrimack Pharmaceuticals Announces Initiation ... [Published GlobeNewswire: Acquisitions News - Aug 11 2014]
Lion Biotechnologies Enters Clinical Trial Gran... [Published GlobeNewswire: Acquisitions News - Jul 30 2014]
Galectin Therapeutics Announces First Patient D... [Published GlobeNewswire: Acquisitions News - Jul 22 2014]
Seragon Pharmaceuticals Announces Acquisition A... [Published GlobeNewswire: Acquisitions News - Jul 02 2014]
1 2 3 4 5
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.